Various forms of DT-antiCCR4 fusions have been investigated, including monovalent DT390-scFv, bivalent DT390-biscFv, and DT390-Fold-back diabody with the aims of directly depleting both human CCR4+ tumor cells and CCR4+ Tregs as a combined cancer treatment. This evidence concerns the gene CCR4 and neoplasm.